Promisingly, all new lipopeptides with a linker exhibited dramatically increased activity in inhibiting the S protein cell fusion and SARS-CoV-2 pseudovirus infection, as indicated by their 12∼24-fold decreased IC50 values (Figure 4(D–F)). This evidence concerns the gene PROS1 and COVID-19.